The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1639
December 13, 2021
View Complete Issue         Table of Contents 2019 
Varenicline Nasal Spray (Tyrvaya) for Dry Eye Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Varenicline Nasal Spray (Tyrvaya) for Dry Eye Disease
December 13, 2021 (Issue: 1639)
Tyrvaya (Oyster Point), a nasal spray formulation of the cholinergic agonist varenicline, has been approved by the FDA for treatment of dry eye disease. It is the first nasal spray to be approved in the US for this indication. An oral formulation...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Varenicline Nasal Spray (Tyrvaya) for Dry Eye Disease
Article code: 1639b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.